Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 2,282 INR
Change Today -23.65 / -1.03%
Volume 1.7K
As of 11:47 PM 07/5/15 All times are local (Market data is delayed by at least 15 minutes).

natco pharma ltd (NTCPH) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/7/15 - 2,710
52 Week Low
07/7/14 - 975.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NATCO PHARMA LTD (NTCPH)

Related News

No related news articles were found.

natco pharma ltd (NTCPH) Related Businessweek News

No Related Businessweek News Found

natco pharma ltd (NTCPH) Details

NATCO Pharma Limited operates as a pharmaceutical company in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic segments, such as anti-neoplastics, anti-depressants, anti-migraine, anti- osteoporosis, anti-asthma, proton pump inhibitors, and therapeutic peptides. It also provides generic oncology products for the treatment of hematology and solid tumors under the brand names of Geftinat, Erlonat, Veenat, and Sorafenat. In addition, it provides formulations, such as Ondansetron, Anastrozole, Letrozole, Trihexyphenidyl, Cholorquine Phosphate, and Citalopram, as well as is engaged in the retail pharmacy business and contract manufacturing activities. The company was incorporated in 1981 and is headquartered in Hyderabad, India.

Founded in 1981

natco pharma ltd (NTCPH) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

natco pharma ltd (NTCPH) Key Developments

Natco Pharma Limited, Q4 2015 Earnings Call, May 25, 2015

Natco Pharma Limited, Q4 2015 Earnings Call, May 25, 2015

NATCO Pharma Limited Announces Audited Consolidated Earnings Results for the Fourth Quarter and Year Ended March 31, 2015

NATCO Pharma Limited announced audited consolidated earnings results for the fourth quarter and year ended March 31, 2015. For the quarter, the company recorded net revenue of INR 2,040 million against INR 1,937.6 million during fourth quarter of 2014, posting an increase of 5.28%, quarter-on-quarter basis. The profits after tax were recorded as INR 544.4 million, which includes a deferred tax reversal. For the year, the company recorded net revenue of INR 8,401.8 million against INR 7,556.0 million for last year, reflecting a growth of 11.20%. The net profit after tax was INR 1,346.1 million. This includes two exceptional items: a decrease in profit on account of an extraordinary charge of INR 151.3 million due to a legal settlement and an increase in profit on account of a reversal of deferred tax liability of INR 311.7 million.

Natco Pharma Limited, Special/Extraordinary Shareholders Meeting, Jun 27, 2015

Natco Pharma Limited, Special/Extraordinary Shareholders Meeting, Jun 27, 2015., at 10:30 Indian Standard Time. Location: Jubilee Hills International Centre. Agenda: To consider the increase of equity investment percentage in the company; to further issue shares or convertible securities to foreign institutional investors; to cosnider the merger of Natco Organics Limited into the company; and to approve ESOP scheme under SEBI regulation, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NTCPH:IN 2,281.85 INR -23.65

NTCPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NTCPH.
View Industry Companies

Industry Analysis


Industry Average

Valuation NTCPH Industry Range
Price/Earnings 55.8x
Price/Sales 9.7x
Price/Book 8.9x
Price/Cash Flow 50.0x
TEV/Sales 9.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NATCO PHARMA LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at